Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Feb. 15 Quick Takes: Emergent deal to grow Bavarian Nordic footprint in U.S., Europe

Plus: Maxion raises series A to develop mAbs against ion channels, GPCRs and updates from Arrowhead, Moderna, Galera, Codagenix, Nanite

February 15, 2023 10:43 PM UTC

As part of its bid to become the largest pure-play vaccine company,  Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) is paying $270 million up front to Emergent BioSolutions Inc. (NYSE:EBS) to acquire a trio of travel vaccines: Vivotif for typhoid fever, Vaxchora for cholera and a candidate targeting Chikungunya, with Phase III data expected in 2H23. Bavarian Nordic said the deal will build its U.S. presence with the addition of R&D facilities and commercial operations, bolster its manufacturing capabilities via the addition of a Swiss biologics facility and increase its scale in Europe. Emergent is eligible for $110 million in milestones.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is planning to conduct a Phase II trial of ARO-PNPLA3 on its own after Johnson & Johnson (NYSE:JNJ) returned rights to the therapy to treat non-alcoholic steatohepatitis. The pharma held its rights under a 2018 deal; Arrowhead said J&J’s decision stemmed from a strategic portfolio review. New Phase I data showed that the PNPLA3-targeting therapy led to liver fat reductions of up to 40% among patients homozygous for the I148M mutation...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article